Gilead Sciences Inc (GILD)

67.48
0.22 0.33
NASDAQ : Health Care
Prev Close 67.26
Open 67.36
Day Low/High 67.10 / 67.56
52 Wk Low/High 77.92 / 120.37
Volume 1.35M
Avg Volume 10.69M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 87.72B
EPS 10.10
P/E Ratio 6.75
Div & Yield 2.08 (3.10%)

Latest News

Time to Call It Quits on Gilead Sciences

This position just hasn't worked for us.

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months

The top 64 companies taking a trip to TheStreet's 2017 Market Bracket Challenge tournament.

Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round

Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round

Jim Cramer is bullish on Delta, Barracuda Networks, STMicroelectronics, UnitedHealth Group.

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.

Google, Apple, Starbucks: Doug Kass' Views

Google, Apple, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on the state of the market, and notices that the irrational might now be rationalized.

Incyte Pops on Continued Gilead Takeout Speculation

Incyte Pops on Continued Gilead Takeout Speculation

Shares were up 8% during intraday trading.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

4 Value Stock Picks for an Elevated Market

4 Value Stock Picks for an Elevated Market

Taking from Ben Graham's playbook, this handful of stocks have reasonable valuations in an extended market.

4 Value Stock Picks for an Elevated Market

4 Value Stock Picks for an Elevated Market

Taking from Ben Graham's playbook, this handful of stocks have reasonable valuations in an extended market.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Gilead Sciences, Inc. is the #45 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

Gilead Sciences To Present At The Barclays Global Healthcare Conference On Tuesday, March 14

Gilead Sciences To Present At The Barclays Global Healthcare Conference On Tuesday, March 14

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

IBM, Apple, Amazon: Doug Kass' Views

IBM, Apple, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on peak housing, and also discusses Fannie Mae and Freddie Mac's recent kneecapping.

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Jim Cramer is bullish on Incyte, Skyworks Solutions, Western Digital, Constellation Brands and more.

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.

Sarepta Leads Biotech Movers on Voucher Deal News

Sarepta Leads Biotech Movers on Voucher Deal News

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Cramer shares his views on how tired he is of hearing about Kool-Aid, and wonders if Apple could be valued as a consumer-products company one day.

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Better Late Than Never, Right?

Some positions call for overdue action, such as getting out of GoDaddy.

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Gilead Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya® For Treatment Of HIV-1 In Treatment-Naïve Adults

Gilead Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya® For Treatment Of HIV-1 In Treatment-Naïve Adults

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya ® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine...

No Bottoming Signs Yet for Gilead

No Bottoming Signs Yet for Gilead

Don't fight the trend of this stock.

Gilead Has 'Good News' But is it Enough?

Gilead Has 'Good News' But is it Enough?

Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.